- Home
- IFN vs RIGL Comparison
IFN vs RIGL Comparison
Compare IFN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFN
- RIGL
- Stock Information
- Founded
- IFN 1993
- RIGL 1996
- Country
- IFN Singapore
- RIGL United States
- Employees
- IFN N/A
- RIGL N/A
- Industry
- IFN Finance/Investors Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- IFN Finance
- RIGL Health Care
- Exchange
- IFN Nasdaq
- RIGL Nasdaq
- Market Cap
- IFN 614.0M
- RIGL 537.6M
- IPO Year
- IFN N/A
- RIGL 2000
- Fundamental
- Price
- IFN $14.25
- RIGL $46.89
- Analyst Decision
- IFN
- RIGL Strong Buy
- Analyst Count
- IFN 0
- RIGL 5
- Target Price
- IFN N/A
- RIGL $43.20
- AVG Volume (30 Days)
- IFN 135.2K
- RIGL 740.2K
- Earning Date
- IFN 01-01-0001
- RIGL 11-04-2025
- Dividend Yield
- IFN 8.68%
- RIGL N/A
- EPS Growth
- IFN N/A
- RIGL 2698.26
- EPS
- IFN N/A
- RIGL 6.20
- Revenue
- IFN N/A
- RIGL $282,076,000.00
- Revenue This Year
- IFN N/A
- RIGL $59.93
- Revenue Next Year
- IFN N/A
- RIGL N/A
- P/E Ratio
- IFN N/A
- RIGL $7.47
- Revenue Growth
- IFN N/A
- RIGL 79.13
- 52 Week Low
- IFN $14.40
- RIGL $14.63
- 52 Week High
- IFN $21.25
- RIGL $47.27
- Technical
- Relative Strength Index (RSI)
- IFN 31.61
- RIGL 69.47
- Support Level
- IFN $15.06
- RIGL $34.00
- Resistance Level
- IFN $15.43
- RIGL $47.26
- Average True Range (ATR)
- IFN 0.19
- RIGL 3.17
- MACD
- IFN -0.04
- RIGL 0.99
- Stochastic Oscillator
- IFN 12.19
- RIGL 96.82
About IFN India Fund Inc. (The)
India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others. Geographically, all the business activity functions through the market of the United States.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.